
FDA Issues Guidance on Pediatric Studies of Molecularly Targeted Oncology Drugs
The guidance addresses implementation of amendments made by the FDA Reauthorization Act of 2017.
FDA published
Specifically, the document discusses regulatory considerations such as molecular target, determination of relevance, target lists, recommended studies, and rare cancers. It also addresses international collaboration in development of these drugs.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.